Current treatments of chronic immune-mediated demyelinating polyneuropathies

Muscle and Nerve

Volumn 39, Issue 5, 2009, Pages 563-578

  Brannagan III, Thomas H ^a  

^a NEUROLOGICAL INSTITUTE   (United States)

Author keywords

Chronic inflammatory demyelinating polyradiculoneuropathy; Cyclophosphamide; Intravenous immunoglobulin; Multifocal motor neuropathy; Myelin associated glycoprotein

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; AZATHIOPRINE; BETA1A INTERFERON; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CHLORAMBUCIL; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEXAMETHASONE; DIPHENHYDRAMINE; ETANERCEPT; FLUDARABINE; GLUCOCORTICOID; HYDROCORTISONE SODIUM SUCCINATE; IMMUNOGLOBULIN; INTERFERON; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NIMODIPINE; PARACETAMOL; PLACEBO; PREDNISONE; PROPRANOLOL; RITUXIMAB; UNINDEXED DRUG; VITAMIN D;

ACUTE LUNG INJURY; AGITATION; ALOPECIA; ANAPHYLAXIS; ANTIMYELIN ASSOCIATED GLYCOPROTEIN NEUROPATHY; APHASIA; APLASTIC ANEMIA; ARTHRITIS; ASEPTIC MENINGITIS; ASEPTIC NECROSIS; AUTOIMMUNE DISEASE; AUTOIMMUNE THYROIDITIS; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; B CELL LEUKEMIA; B CELL LYMPHOMA; BLADDER CANCER; BLOOD TOXICITY; BONE ATROPHY; BONE MARROW SUPPRESSION; BRAIN VASOSPASM; CATARACT; CENTRAL NERVOUS SYSTEM DISEASE; CENTRAL NERVOUS SYSTEM LYMPHOMA; CENTRAL NERVOUS SYSTEM TUMOR; CENTRAL RETINA VEIN OCCLUSION; CHILD GROWTH; CHILL; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; CORTICOSTEROID THERAPY; CRYOGLOBULINEMIC VASCULITIS; CUSHINGOID SYNDROME; CYTOKINE RELEASE SYNDROME; CYTOMEGALOVIRUS INFECTION; DEEP VEIN THROMBOSIS; DEMYELINATING NEUROPATHY; DEMYELINATION; DEPRESSION; DETERIORATION; DIABETES MELLITUS; DIARRHEA; DISORIENTATION; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED CANCER; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG WITHDRAWAL; DYSPNEA; ECZEMA; ENDOCRINE DISEASE; ERYTHEMA; ERYTHEMA MULTIFORME; EUPHORIA; FEVER; FLU LIKE SYNDROME; FRACTURE; FRAGILITY FRACTURE; GASTRITIS; GASTROINTESTINAL HEMORRHAGE; GLAUCOMA; GUILLAIN BARRE SYNDROME; HEART INFARCTION; HEARTBURN; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOLYTIC ANEMIA; HEMORRHAGIC CYSTITIS; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOTENSION; HYPOTHYROIDISM; IMMUNE COMPLEX ARTHRITIS; IMMUNOGLOBULIN A DEFICIENCY; IMMUNOMODULATION; IMMUNOPATHOLOGY; IMMUNOTHERAPY; INFECTION; INFECTION SENSITIVITY; INFERTILITY; INSOMNIA; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LEUKOCYTE COUNT; LEUKOPENIA; LIVER TOXICITY; LUNG EMBOLISM; LUPUS LIKE SYNDROME; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MACULOPAPULAR RASH; MAINTENANCE THERAPY; MALAISE; MIGRAINE; MOOD CHANGE; MUCOCUTANEOUS REACTION; MULTIFOCAL MOTOR NEUROPATHY; MULTIPLE SCLEROSIS; MYALGIA; MYOPATHY; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; NONHODGKIN LYMPHOMA; OLIGURIA; OSTEOPENIA; PANCREATITIS; PLASMAPHERESIS; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PRURITUS; PURPURIC ERYTHEMA; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; RECURRENT DISEASE; RESTLESSNESS; REVIEW; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; SKIN; SKIN CANCER; SKIN MANIFESTATION; STROKE; TERATOGENICITY; THROMBOCYTOISIS; THROMBOEMBOLISM; TREATMENT OUTCOME; TREMOR; URTICARIA; UVEITIS; VASCULITIC RASH; VASCULITIS; VASOMOTOR DISORDER; VIRUS PNEUMONIA; VIRUS TRANSMISSION; VISUAL DISORDER; VOMITING; WEIGHT GAIN; WOUND HEALING IMPAIRMENT;

DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MYELIN-ASSOCIATED GLYCOPROTEIN; PERIPHERAL NERVOUS SYSTEM DISEASES; POLYNEUROPATHIES; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING;

EID: 65949107332     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.21277     Document Type: Review

References (211)

1. Ahlmen J, Andersen O, Hallgren G, et al. Positive effects of tacrolimus in a case of CIDP. Transplant Proc 1998;30:4194. (Pubitemid 29013203)
2. American College of Rheumatology Ad Hoc Committee on Glucocorticoid- Induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum 2001;44:1496-1503.
3. Axelson HW, Oberg G, Askmark H. Successful repeated treatment with high dose cyclophosphamide and autologous blood stem cell transplantation in CIDP. J Neurol Neurosurg Psychiatry 2008;79:612-614.
4. Ayliffe W, Haeney M, Roberts SC, et al. Uveitis after antineutrophil cytoplasmic antibody contamination of immunoglobulin replacement therapy. Lancet 1992;339:558-559.
5. Azulay JP, Blin O, Pouget J, et al. Intravenous immunoglobulin treatment in patients with motor-neuron syndromes associated with anti-GM1 antibodies - a double-blind, placebo-controlled study. Neurology 1994;44:429-432.
6. Barnett MH, Pollard JD, Davies L, et al. Cyclosporine A in resistant chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 1998;21:454-460.
7. Barohn RJ, Kissel JT, Warmolts JR, et al. Chronic inflammatory demyelinating polyradiculoneuropathy - clinical characteristics, course, and recommendations for diagnostic criteria. Arch Neurol 1989;46:878-884 (Pubitemid 19199372)
8. Barucha C, McMillan JC. Eczema after intravenous infusion of immunoglobulin. Br Med J (Clin Res Ed) 1987;295:1141. (Pubitemid 17151288)
9. Ben Chetrit E, Putterman C. Transient neutropenia induced by intravenous immune globulin. N Engl J Med 1992;326:270-271.
10. Benedetti L, Briani C, Grandis M, et al. Predictors of response to rituximab in patients with neuropathy and antimyelin associated glycoprotein immunoglobulin M. J Peripher Nerv Syst 2007;12:102-107. (Pubitemid 46906332)
11. Benedetti L, Franciotta D, Beronio A, et al. Rituximab efficacy in CIDP associated with idiopathic thrombocytopenic purpura. Muscle Nerve 2008;38:1076-1077.
12. Berlex, Inc. Genzyme and Schering AG announce interim results from trial of Campath for multiple sclerosis [press release]; 2006.
13. Bertorini TE, Nance AM, Horner LH, et al. Complications of intravenous gammaglobulin in neuromuscular and other diseases. Muscle Nerve 1996;19:388-391.
14. Bjoro K, Froland SS, Yun Z, et al. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med 1994;331:1607-1611.
15. Black K, Koraibaa K, Souayah N, Dawson K, Saio P, Cros D. Assessment of IVIg efficacy in chronic inflammatory demyelinating polyneuropathy using posturography: a pilot study. Muscle Nerve 2003;28(suppl):S90.
16. Blasczyk R, Westhoff U, Grosse-Wilde H. Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparations. Lancet 1993;341:789-790. (Pubitemid 23096288)
17. Bleeker WK, Teeling JL, Verhoeven AJ, et al. Vasoactive side effects of intravenous immunoglobulin preparations in a rat model and their treatment with recombinant platelet-activating factor acetylhydrolase. Blood 2000;95:1856-1861.
18. Blume G, Pestronk A, Goodnough LT. Anti-MAG antibody-associated polyneuropathies - improvement following immunotherapy with monthly plasma-exchange and IV-cyclophosphamide. Neurology 1995;45:1577-1580.
19. Bower LR, Brey RL, Roger SJ, Stroncek DF, Jackson CE. Intravenous immunoglobulin-induced neutropenia. Ann Neurol 1994;36:291.
20. Brannagan TH. Intravenous gammaglobulin (IVIg) for treatment of CIDP and related immune-mediated neuropathies. Neurology 2002;59(suppl):S33-S40. (Pubitemid 36076547)
21. Brannagan TH III, Alaedini A, Gladstone DE. High-dose cyclophosphamide without stem cell rescue for refractory multifocal motor neuropathy. Muscle Nerve 2006;34:246-250.
22. Brannagan TH, Nagle KJ, Lange DJ, et al. Complications of intravenous immune globulin treatment in neurologic disease. Neurology 1996;47:674-677.
23. Brannagan TH, Pradhan A, Heiman-Patterson T, et al. High-dose cyclophosphamide without stem-cell rescue for refractory CIDP. Neurology 2002;58:1856-1858.
24. Brecher ME. Plasma exchange: why we do what we do. J Clin Apher 2002;17:207-211. (Pubitemid 36015436)
25. Briani C, Zara G, Zambello R, et al. Rituximab-responsive CIDP. Eur J Neurol 2004;11:788.
26. Brodsky RA, Petri M, Smith BD, et al. Immunoablative high-dose cyclophosphamide without stem-cell rescue for refractory, severe autoimmune disease. Ann Intern Med 1998;129:1031-1035.
27. Brodsky RA, Sensenbrenner LL, Smith BD, et al. Durable treatment-free remission after high-dose cyclophosphamide therapy for previously untreated severe aplastic anemia. Ann Intern Med 2001;135:477-483.
28. Brox AG, Cournoyer D, Sternbach M, et al. Hemolytic anemia following intravenous gamma globulin administration. Am J Med 1987;82:633-635.
29. Burks AW, Sampson HA, Buckley RH. Anaphylactic reactions after gamma-globulin administration in patients with hypogammaglobulinemia - detection of IgE antibodies to IgA. N Engl J Med 1986;314:560-564. (Pubitemid 16128065)
30. Caress JB, Cartwright MS, Donofrio PD, et al. The clinical features of 16 cases of stroke associated with administration of IVIg. Neurology 2003;60:1822-1824.
31. Carpo M, Cappellari A, Mora G, et al. Deterioration of multifocal motor neuropathy after plasma exchange. Neurology 1998;50:1480-1482.
32. Center for Disease Control and Prevention. Renal insufficiency and failure associated with immune globulin intravenous therapy - United States, 1985-1998. Morbid Mortal Wkly Rep 1999;48:518-521.
33. Center for Disease Control and Prevention. Safety of therapeutic immune globulin preparations with respect to transmission of human T-lymphotropic virus type III/lymphadenopathy-associated virus infection. Morbid Mortal Wkly Rep 1986;35:231-233.
34. Chan-Lam D, Fitzsimons EJ, Douglas WS. Alopecia after immunoglobulin infusion. Lancet 1987;i:1436.
35. Chatot-Henry C, Smadja D, Mehdaoui H, et al. Acute renal insufficiency and cerebral infarction during high-dose intravenous immunoglobulin therapy [in French]. Rev Med Interne 1998;19:914-916.
36. Chaudhry V, Cornblath DR, Griffin JW, et al. Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. Neurology 2001;56:94-96.
37. Chin RL, Latov N, Sander HW, et al. Chronic inflammatory demyelinating polyneuropathy presenting as cryptogenic sensory polyneuropathy. J Peripher Nerv Syst 2004;9:128-133.
38. Chin RL, Sherman WH, Sander HW et al. Etanercept (Enbrel (R)) therapy for chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 2003;210:19-21.
39. Choudhary PP, Hughes RA. Long-term treatment of chronic inflammatory demyelinating polyradiculoneuropathy with plasma exchange or intravenous immunoglobulin. Q J Med 1995;88:493-502.
40. Choudhary PP, Thompson N, Hughes RA. Improvement following interferon beta in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol 1995;242:252-253.
41. Coles AJ, Cox A, Le Page E, et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 2006;253:98-108.
42. Coles AJ, Wing MG, Molyneux P, et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 1999;46:296-304.
43. Coletta AP, Clark AL, Banarjee P, et al. Clinical trials update: RENEWAL (RENAISSANCE and RECOVER) and ATTACH. Eur J Heart Fail 2002;4:559-561.
44. Comi G, Roveri L, Swan A, et al. A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. J Neurol 2002;249:1370-1377.
45. Constantinescu CS, Chang AP, McCluskey LF. Recurrent migraine and intravenous immune globulin therapy. N Engl J Med 1993;329:583-584. (Pubitemid 23232638)
46. Dalakas MC. Intravenous immune globulin therapy for neurologic diseases. Ann Intern Med 1997;126:721-730. (Pubitemid 27184044)
47. Dalakas MC. High-dose intravenous immunoglobulin and serum viscosity - risk of precipitating thromboembolic events. Neurology 1994;44:223-226. (Pubitemid 24070955)
48. Dalakas MC. Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines. Muscle Nerve 1999;22:1479-1497. (Pubitemid 29508298)
49. Dalakas MC. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. Pharmacol Ther 2004;102:177-193.
50. Dalakas MC, Engel WK. Chronic relapsing (dysimmune) polyneuropathy - pathogenesis and treatment. Ann Neurol 1981;9:134-145. (Pubitemid 11120646)
51. Dalakas MC, Quarles RH, Farrer RG, et al. A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Ann Neurol 1996;40:792-795.
52. Dalakas MC, Rakocevic G, Salajegheh MK, et al. A double-blind, placebo-controlled study of rituximab in patients with anti-MAG antibody-demyelinating polyneuropathy (A-MAG-DP). Neurology 2007;68:A214.
53. Dantal J, Hourmant M, Cantarovich D, et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporine regimens. Lancet 1998;351:623-628.
54. de Albuquerque CR, Sato MN, Silva Duarte AJ. IgG anti-IgA subclasses in common variable immunodeficiency and association with severe adverse reactions to intravenous immunoglobulin therapy. J Clin Immunol 2000;20:77-82. (Pubitemid 30210110)
55. De Luca LG, Lugaresi A, Iarlori C, et al. Prednisone and plasma exchange improve suppressor cell function in chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol 1999;95:190-194.
56. Di Troia A, Carpo M, Meucci N, et al. Clinical features and anti-neural reactivity in neuropathy associated with IgG monoclonal gammopathy of undetermined significance. J Neurol Sci 1999;164:64-71.
57. Donaghy M, Mills KR, Boniface SJ, et al. Pure motor demyelinating neuropathy - deterioration after steroid treatment and improvement with intravenous immunoglobulin. J Neurolog Neurosurg Psychiatry 1994;57:778-783.
58. Donatini B. Transient renal dysfunction in diabetic patients after IVIg therapy. J Intern Med 1992;232:376.
59. Drachman DB, Jones RJ, Brodsky RA. Treatment of refractory myasthenia: "rebooting" with high-dose cyclophosphamide. Ann Neurol 2003;53:29-34.
60. Dyck PJ, Daube J, O'Brien P, et al. Plasma-exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med 1986;314:461-465.
61. Dyck PJ, Dyck PJB. Atypical varieties of chronic inflammatory demyelinating neuropathies. Lancet 2000;355:1293-1294. (Pubitemid 30198999)
62. Dyck PJ, Litchy WJ, Kratz KM, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 1994;36:838-845.
63. Dyck PJ, O'Brien P, Swanson C, et al. Combined azathioprine and prednisone in chronic inflammatory-demyelinating polyneuropathy. Neurology 1985;35:1173-1176.
64. Dyck PJ, O'Brien PC, Oviatt KF, et al. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol 1982;11:136-141.
65. Echaniz-Laguna A, Battaglia F, Ellero B, et al. Chronic inflammatory demyelinating polyradiculoneuropathy in patients with liver transplantation. Muscle Nerve 2004;30:501-504.
66. Elkayam O, Paran D, Milo R, et al. Acute myocardial infarction associated with high dose intravenous immunoglobulin infusion for autoimmune disorders. A study of four cases. Ann Rheum Dis 2000;59:77-80. (Pubitemid 30303904)
67. Ellie E, Combe C, Ferrer X. High-dose intravenous immune globulin and acute renal failure. N Engl J Med 1992;327:1032-1033.
68. Federico P, Zochodne DW, Hahn AF, et al. Multifocal motor neuropathy improved by IVIg - randomized, double-blind, placebo-controlled study. Neurology 2000;55:1256-1262.
69. Feldman EL, Bromberg MB, Albers JW, et al. Immunosuppressive treatment in multifocal motor neuropathy. Ann Neurol 1991;30:397-401.
70. Festic E, Gajic O, Limper AH, et al. Acute respiratory failure due to Pneumocystis pneumonia in patients without human immunodeficiency virus infection - outcome and associated features. Chest 2005;128:573-579.
71. Frampton JE, Wagstaff AJ. Alemtuzumab. Drugs 2003;63:1229-1243.
72. Garside H, Stevens A, Farrow S, et al. Glucocorticoid ligands specify different interactions with NF-kappa B by allosteric effects on the glucocorticoid receptor DNA binding domain. J Biol Chem 2004;279:50050-50059.
73. Gladstone DE, Brannagan TH III, Schwartzman RJ, et al. High dose cyclophosphamide for severe refractory myasthenia gravis. J Neurol Neurosurg Psychiatry 2004;75:789-791.
74. Gladstone DE, Golightly MG, Brannagan TH III. High dose cyclophosphamide preferentially targets naive T (CD45/CD4/RA+) cells in CIDP and MS patients. J Neuroimmunol 2007;190:121-126. (Pubitemid 47625598)
75. Gladstone DE, Prestrud AA, Brannagan TH III. High-dose cyclophosphamide results in long-term disease remission with restoration of a normal quality of life in patients with severe refractory chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst 2005;10:11-16. (Pubitemid 40289577)
76. Gluck OS, Murphy WA, Hahn TJ, et al. Bone loss in adults receiving alternate day glucocorticoid therapy. A comparison with daily therapy. Arthritis Rheum 1981;24:892-898.
77. Good JL, Chehrenama M, Mayer RF, et al. Pulse cyclophosphamide therapy in chronic inflammatory demyelinating polyneuropathy. Neurology 1998;51:1735-1738.
78. Goodman & Gilman's pharmacological basis of therapeutics. New York: McGraw-Hill; 2005.
79. Gorson K, Hughes R, Cros D, et al. Efficacy of interferon beta-1a in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Neurology 2008;70:A369.
80. Gorson KC, Allam G, Ropper AH. Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology 1997;48:321-328. (Pubitemid 27087596)
81. Gorson KC, Amato AA, Ropper AH. Efficacy of mycophenolate mofetil in patients with chronic immune demyelinating polyneuropathy. Neurology 2004;63:715-717. (Pubitemid 39100833)
82. Gorson KC, Natarajan N, Ropper AH, et al. Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial. Muscle Nerve 2007;35:66-69.
83. Gorson KC, Ropper AH. Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): a review of clinical syndromes and treatment approaches in clinical practice. J Clin Neuromuscul Dis 2003;4:174-189. (Pubitemid 38404428)
84. Gorson KC, Ropper AH, Clark BD, et al. Treatment of chronic inflammatory demyelinating polyneuropathy with interferon-alpha 2a. Neurology 1998;50:84-87.
85. Gorson KC, Ropper AH, Weinberg DH, et al. Treatment experience in patients with anti-myelin-associated glycoprotein neuropathy. Muscle Nerve 2001;24:778-786.
86. Grillo JA, Gorson KC, Ropper AH, et al. Rapid infusion of intravenous immune globulin in patients with neuromuscular disorders. Neurology 2001;57:1699-1701.
87. Grillo-Lopez AJ, Hedrick E, Rashford M, et al. Rituximab: ongoing and future clinical development. Semin Oncol 2002;29:105-112.
88. Hadden RDM, Sharrack B, Bensa S, et al. Randomized trial of interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 1999;53:57-61.
89. Hahn AF, Bolton CF, Pillay N, et al. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. Brain 1996;119:1055-1066.
90. Hahn AF, Bolton CF, Zochodne D, et al. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study. Brain 1996;119:1067-1077.
91. Harkness K, Howell SJ, Davies Jones GAB. Encephalopathy associated with intravenous immunoglobulin treatment for Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 1996;60:586. (Pubitemid 26147905)
92. Harter JG, Reddy WJ, Thorn GW. Studies on intermittent corticosteroid dosage regimen. N Engl J Med 1963;269:591-596.
93. Hayakawa F, Imada K, Towatari M, et al. Life-threatening human parvovirus B19 infection transmitted by intravenous immune globulin. Br J Haematol 2002;118:1187-1189.
94. Hirst C, Raasch S, Llewelyn G, et al. Remission of chronic inflammatory demyelinating polyneuropathy after alemtuzumab (Campath 1H). J Neurol Neurosurg Psychiatry 2006;77:800-802.
95. Howse M, Bindoff L, Carmichael A. Facial vasculitic rash associated with intravenous immunoglobulin. BMJ 1998;317:1291.
96. Hughes R, Bensa S, Willison H, et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001;50:195-201.
97. Hughes RA, Bouche P, Cornblath DR, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol 2006;13:326-332.
98. Hughes RA, Donofrio P, Bril V, et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 2008;7:136-144.
99. Hughes RA, Swan AV, van Doorn PA. Cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2003;CD003280.
100. Jin F, Balthasar JP. Mechanisms of intravenous immunoglobulin action in immune thrombocytopenic purpura. Hum Immunol 2005;66:403-410. (Pubitemid 40615796)
101. Jones RJ, Barber JP, Vala MS, et al. Assessment of aldehyde dehydrogenase in viable cells. Blood 1995;85:2742-2746.
102. Katz JS, Saperstein DS, Gronseth G, et al. Distal acquired demyelinating symmetric neuropathy. Neurology 2000;54:615-620.
103. Khanna D, McMahon M, Furst DE. Safety of tumour necrosis factor-alpha antagonists. Drug Safety 2004;27:307-324.
104. Kissel JT. The treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Semin Neurol 2003;23:169-179. (Pubitemid 36910117)
105. Knecht H, Baumberger M, Tobon A, et al. Sustained remission of CIDP associated with Evans syndrome. Neurology 2004;63:730-732.
106. Kobayashi RH. Immunoglobulin therapy. In: Petz LD, Swisher ER, eds. Clinical practice of transfusion medicine. New York: Churchill Livingstone; 1995. p 985-1010.
107. Koffman B, Dalakas MC. Effect of high-dose intravenous immunoglobulin on serum chemistry, hematology, and lymphocyte subpopulations: assessments based on controlled treatment trials in neurological diseases. Muscle Nerve 1997;20:1102-1107. (Pubitemid 27352091)
108. Koller H, Kieseier BC, Jander S et al. Chronic inflammatory demyelinating polyneuropathy. N Engl J Med 2005;352:1343-1356.
109. Kubori T, Mezaki T, Kaji R, et al. The clinical usefulness of high-dose intravenous immunoglobulin therapy for chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy [in Japanese]. No To Shinkei 1999;51:127-135.
110. Kuntzer T, Radziwill AJ, Lettry-Trouillat R, et al. Interferon-beta1a in chronic inflammatory demyelinating polyneuropathy. Neurology 1999;53:1364-1365.
111. Latov N, Hays AP, Sherman WH. Peripheral neuropathy and anti-MAG antibodies. Crit Rev Neurobiol 1988;3:301-332. (Pubitemid 18208719)
112. Latov N, Renaud S. Effector mechanisms in anti-MAG antibody-mediated and other demyelinating neuropathies. J Neurol Sci 2004;220:127-129. (Pubitemid 38622112)
113. Latov N, Sherman WH, Vlahides G. Therapy of neuropathy associated with anti-MAG IgM monoclonal gammopathy with Rituxan. Neurology 1999;52:A551.
114. Lederman HM, Roifman CM, Lavi S, et al. Corticosteroids for prevention of adverse reactions to intravenous immune serum globulin infusions in hypogammaglobulinemic patients. Am J Med 1986;81:443-446.
115. Leger JM, Chassande B, Musset L, et al. Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain 2001;124:145-153.
116. Levine TD, Pestronk A. IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab. Neurology 1999;52:1701-1704.
117. Lewis RA, Eilender DS, Li J. Rituximab is effective therapy for some patients with IgM kappa related polyneuropathy: a report of results in 8 patients. Neurology 2003;60(suppl 1):A491.
118. Lipsky JJ. Mycophenolate mofetil. Lancet 1996;348:1357-1359. (Pubitemid 26383778)
119. Lisak RP. Arthritis associated with circulating immune complexes following administration of intravenous immunoglobulin therapy in a patient with chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 1996;135:85-88. (Pubitemid 26019027)
120. Lopate G, Pestronk A, Al Lozi M. Treatment of chronic inflammatory demyelinating polyneuropathy with high-dose intermittent intravenous methylprednisolone. Arch Neurol 2005;62:249-254. (Pubitemid 40204746)
121. Lozsadi DA, Peters G, Sadik HY, et al. Prevention of osteoporosis in glucocorticoid-treated neurology patients. Clin Neurol Neurosurg 2006;108:157-162.
122. Magy L, Chassande B, Maisonobe T, et al. Polyneuropathy associated with IgG/IgA monoclonal gammopathy: a clinical and electrophysiological study of 15 cases. Eur J Neurol 2003;10:677-685.
123. Mahattanakul W, Crawford TO, Griffin JW, et al. Treatment of chronic inflammatory demyelinating polyneuropathy with Cyclosporine-A. J Neurol Neurosurg Psychiatry 1996;60:185-187.
124. Majer RV, Green PJ. Neutropenia caused by intravenous immunoglobulin. Br Med J (Clin Res Ed) 1988;296:1262. (Pubitemid 18119061)
125. Malik U, Oleksowicz L, Latov N, et al. Intravenous gammaglobulin inhibits binding of anti-GM1 to its target antigen. Ann Neurol 1996;39:136-139.
126. Maloney DG, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol 2002;29:2-9.
127. Martin SI, Marty FM, Fiumara K, et al. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis 2006;43:16-24
128. Martina IS, van Doorn PA, Schmitz PI, et al. Chronic motor neuropathies: response to interferon-beta1a after failure of conventional therapies. J Neurol Neurosurg Psychiatry 1999;66:197-201.
129. Mathy I, Gille M, Van Raemdonck F, et al. Neurological complications of intravenous immunoglobulin (IVIg) therapy: an illustrative case of acute encephalopathy following IVIg therapy and a review of the literature. Acta Neurol Belg 1998;98:347-351.
130. McCombe PA, Pollard JD, Mcleod JG. Chronic inflammatory demyelinating polyradiculoneuropathy - a clinical and electrophysiological study of 92 cases. Brain 1987;110:1617-1630. (Pubitemid 18152597)
131. McCrone P, Chisholm D, Knapp M, et al. Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol 2003;10:687-694.
132. Mehndiratta MM, Hughes RA. Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2002;CD002062.
133. Mehndiratta MM, Hughes RA, Agarwal P. Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2004;CD003906.
134. Mendell JR, Barohn RJ, Freimer ML, et al. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2001;56:445-449.
135. Midroni G, Dyck PJ. Chronic inflammatory demyelinating polyradiculoneuropathy: unusual clinical features and therapeutic responses. Neurology 1996;46:1206-1212. (Pubitemid 26159274)
136. Misbah SA, Chapel HM. Adverse effects of intravenous immunoglobulin. Drug Safety 1993;9:254-262. (Pubitemid 23302151)
137. Mitra G, Wong MF, Mozen MM, et al. Elimination of infectious retroviruses during preparation of immunoglobulins. Transfusion (Paris) 1986;26:394-397.
138. Molenaar DS, van Doorn PA, Vermeulen M. Pulsed high dose dexamethasone treatment in chronic inflammatory demyelinating polyneuropathy: a pilot study. J Neurol Neurosurg Psychiatry 1997;62:388-390. (Pubitemid 27199113)
139. Molina JM, Coffineau A, Rain JD, et al. Aseptic meningitis following administration of intravenous immune globulin. Clin Infect Dis 1992;15:564-565.
140. Molloy ES, Cabrese LH. Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk? Autoimmun Rev 2008;8:144-146.
141. Mowzoon N, Sussman A, Bradley WG. Mycophenolate (Cell-Cept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis. J Neurol Sci 2001;185:119-122. (Pubitemid 32318516)
142. Munch C, Anagnostou P, Meyer R, et al. Rituximab in chronic inflammatory demyelinating polyneuropathy associated with diabetes mellitus. J Neurol Sci 2007;256:100-102.
143. Nagamatsu M, Terao S, Misu K, et al. Axonal and perikaryal involvement in chronic inflammatory demyelinating polyneuropathy. J Neurolog Neurosurg Psychiatry 1999;66:727-733.
144. National Institutes of Health Consensus Conference. Intravenous immune globulin: prevention and treatment of disease. JAMA 1990;264:3189-3193.
145. Nemni R, Santuccio G, Calabrese E, et al. Efficacy of cyclosporine treatment in multifocal motor neuropathy. J Neurol 2003;250:1118-1120.
146. Newburger JW, Takahashi M, Beiser AS, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991;324:1633-1639.
147. Nicholls MD, Cummins JC, Davies VJ, et al. Haemolysis induced by intravenously-administered immunoglobulin. Med J Austral 1989;150:404-406.
148. Nobile-Orazio E, Meucci N, Baldini L, et al. Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies. Brain 2000;123:710-717.
149. Nydegger UE. Safety and side effects of i.v. immunoglobulin therapy. Clin Exp Rheumatol 1996;14(suppl 15):S53-S57. (Pubitemid 26270579)
150. O'Dell JR. Drug therapy - therapeutic strategies for rheumatoid arthritis. N Engl J Med 2004;350:2591-2602.
151. Odum J, D'Costa D, Freeth M, et al. Cryoglobulinaemic vasculitis caused by intravenous immunoglobulin treatment. Nephrol Dial Transplant 2001;16:403-406.
152. Oh KT, Boldt HC, Danis RP. Iatrogenic central retinal vein occlusion and hyperviscosity associated with high-dose intravenous immunoglobulin administration. Am J Ophthalmol 1997;124:416-418. (Pubitemid 27383117)
153. Oyama Y, Sufit R, Loh Y, et al. Nonmyeloablative autologous hematopoietic stem cell transplantation for refractory CIDP. Neurology 2007;69:1802-1803.
154. Paolini R, Fabris F, Cella G. Acute myocardial infarction during treatment with intravenous immunoglobulin for idiopathic thrombocytopenic purpura (ITP). Am J Hematol 2000;65:177-178.
155. Pestronk A, Cornblath DR, Ilyas AA, et al. A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Ann Neurol 1988;24:73-78.
156. Pestronk A, Florence J, Miller T, et al. Treatment of IgM antibody associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatry 2003;74:485-489.
157. Pestronk A, Lopate G, Kornberg AJ, et al. Distal lower motor-neuron syndrome with high-titer serum IgM anti-GM1 antibodies - improvement following immunotherapy with monthly plasma-exchange and intravenous cyclophosphamide. Neurology 1994;44:2027-2031.
158. Prineas JW, Mcleod JG. Chronic relapsing polyneuritis. J Neurol Sci 1976;27:427-458.
159. Radis CD, Kahl LE, Baker GL, et al. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid-arthritis - a 20-year follow-up-study. Arthritis Rheum 1995;38:1120-1127.
160. Reid VA, Black KR, Menkes DL, et al. Chronic inflammatory demyelinating polyradiculoneuropathy: diagnosis and management. In: Cros D, editor. Peripheral neuropathy - a practical approach to diagnosis and management. Philadelphia: Lippincott, Williams & Wilkins; 2001. p 85-107.
161. Reinhart WH, Berchtold PE. Effect of high-dose intravenous immunoglobulin therapy on blood rheology. Lancet 1992;339:662-664.
162. Remenyi P, Masszi T, Borbenyi Z, et al. CIDP cured by allogeneic hematopoietic stem cell transplantation. Eur J Neurol 2007;14:E1-E2.
163. Renaud S, Fuhr P, Gregor M, et al. High-dose rituximab and anti-MAG-associated polyneuropathy. Neurology 2006;66:742-744.
164. Renaud S, Gregor M, Fuhr P, et al. Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies. Muscle Nerve 2003;27:611-615.
165. Rizk A, Gorson KC, Kenney L, et al. Transfusion-related acute lung injury after the infusion of IVIg. Transfusion (Paris) 2001;41:264-268.
166. Rojas-Garcia R, Gallardo E, de Andres I, et al. Chronic neuropathy with IgM antiganglioside antibodies: lack of long term response to rituximab. Neurology 2003;61:1814-1816.
167. Rudnicki SA, Harik SI, Dhodapkar M, et al. Nervous system dysfunction in Waldenstrom's macroglobulinemia: response to treatment. Neurology 1998;51:1210-1213.
168. Ruegg SJ, Fuhr P, Steck AJ. Rituximab stabilizes multifocal motor neuropathy increasingly less responsive to IVIg. Neurology 2004;63:2178-2179. (Pubitemid 39636279)
169. Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-induced osteoporosis intervention study group. N Engl J Med 1998;339:292-299. (Pubitemid 28366417)
170. Sabatelli M, Mignogna T, Lippi G, et al. Interferon-alpha may benefit steroid unresponsive chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 1995;58:638-639.
171. Schiavotto C, Ruggeri M, Rodeghiero F. Adverse reactions after high-dose intravenous immunoglobulin: incidence in 83 patients treated for idiopathic thrombocytopenic purpura (ITP) and review of the literature. Haematologica 1993;78:35-40.
172. Schiff RI. Transmission of viral infections through intravenous immune globulin. N Engl J Med 1994;331:1649-1650. (Pubitemid 24372065)
173. 2+ movements and nitric oxide production in endothelial cells. J Biol Chem 1996;271:26473-26476.
174. Sekul EA, Cupler EJ, Dalakas MC. Aseptic-meningitis associated with high-dose intravenous immunoglobulin therapy - frequency and risk-factors. Ann Intern Med 1994;121:259-262.
175. Sherman WH, Latov N, Lange D, et al. Fludarabine for IgM antibody-mediated neuropathies. Ann Neurol 1994;36:326-327.
176. Silverman GJ, Weisman S. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum 2003;48:1484-1492. (Pubitemid 36682354)
177. Stangel M, Toyka KV, Gold R. Mechanisms of high-dose intravenous immunoglobulins in demyelinating diseases. Arch Neurol 1999;56:661-663. (Pubitemid 29266463)
178. Sztajzel R, Floch-Rohr J, Eggimann P. High-dose intravenous immunoglobulin treatment and cerebral vasospasm: a possible mechanism of ischemic encephalopathy? Eur Neurol 1999;41:153-158.
179. Tan E, Hajinazarian M, Bay W, et al. Acute renal failure resulting from intravenous immunoglobulin therapy. Arch Neurol 1993;50:137-139.
180. Thomas CF, Limper AH. Pneumocystis pneumonia. N Engl J Med 2004;350:2487-2498.
181. Toyka KV, Gold R. The pathogenesis of CIDP - rationale for treatment with immunomodulatory agents. Neurology 2003;60(suppl):S2-S7. (Pubitemid 36459463)
182. Umapathi T, Hughes R. Mycophenolate in treatment-resistant inflammatory neuropathies. Eur J Neurol 2002;9:683-685. (Pubitemid 36961297)
183. Uncini A, Di MA, De Angelis MV, et al. Minimal and asymptomatic chronic inflammatory demyelinating polyneuropathy. Clin Neurophysiol 1999;110:694-698.
184. Vallat JM, Hahn AF, Leger JM, et al. Interferon beta-1a as an investigational treatment for CIDP. Neurology 2003;60(suppl):S23-S28.
185. van den Berg LH, Franssen H, Wokke JHJ. The long-term effect of intravenous immunoglobulin treatment in multifocal motor neuropathy. Brain 1998;121:421-428. (Pubitemid 28116339)
186. Van den Berg-Vos RM, van den Berg LH, Franssen H, et al. Treatment of multifocal motor neuropathy with interferon-beta1A. Neurology 2000;54:1518-1521.
187. van Schaik IN, Bouche P, Illa I, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Eur J Neurol 2006;13:802-808.
188. Van Staa TP, Leufkens HG, Abenhaim L, et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000;15:993-1000.
189. van Schaik, I, van den Berg LH, de HR, et al. Intravenous immunoglobulin for multifocal motor neuropathy. Cochrane Database Syst Rev 2005;CD004429.
190. van den Berg LH, Kerkhoff H, Oey PL, et al. Treatment of multifocal motor neuropathy with high-dose intravenous immunoglobulins - a double-blind, placebo-controlled study. J Neurol Neurosurg Psychiatry 1995;59:248-252.
191. van Doorn PA. Treatment of patients with chronic inflammatory demyelinating polyneuropathy. Rev Neurol (Paris) 1996;152:383-386. (Pubitemid 26228354)
192. van Doorn PA, Vermeulen M, Brand A, et al. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy - clinical and laboratory characteristics associated with improvement. Arch Neurol 1991;48:217-220.
193. Veenstra DL, Best JH, Hornberger J, et al. Incidence and long-term cost of steroid-related side effects after renal transplantation. Am J Kidney Dis 1999;33:829-839.
194. Vera-Ramirez M, Charlet M, Parry GJ. Recurrent aseptic meningitis complicating intravenous immunoglobulin therapy for chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 1992;42:1636-1637.
195. Vermeulen M, Van Oers MH. Successful autologous stem cell transplantation in a patient with chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 2002;72:127-128. (Pubitemid 34073115)
196. Vermeulen M, Van Oers MHJ. Relapse of chronic inflammatory demyelinating polyneuropathy 5 years after autologous stem cell transplantation. J Neurol Neurosurg Psychiatry 2007;78:1154.
197. Vernino S, Salomao DR, Habermann TM, O'Neill BP. Primary CNS lymphoma complicating treatment of myasthenia gravis with mycophenolate mofetil. Neurology 2005;65:639-641. (Pubitemid 41170735)
198. Viala K, Renie L, Maisonobe T, et al. Follow-up study and response to treatment in 23 patients with Lewis-Sumner syndrome. Brain 2004;127:2010-2017.
199. Villa AM, Garcea O, Di Egidio M, et al. Interferon beta-1a in chronic inflammatory demyelinating polyneuropathy: case report. Arq Neuropsiquiatr 2004;62:892-894. (Pubitemid 39361846)
200. Voltz R, Rosen FV, Yousry T, et al. Reversible encephalopathy with cerebral vasospasm in a Guillain-Barré syndrome patient treated with intravenous immunoglobulin. Neurology 1996;46:250-251.
201. Vucic S, Black KR, Chong PS, et al. Multifocal motor neuropathy: decrease in conduction blocks and reinnervation with long-term IVIg. Neurology 2004;63:1264-1269.
202. Wallach S, Cohen S, Reid DM, et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 2000;67:277-285.
203. Weinstein R. Therapeutic apheresis in neurological disorders. J Clin Apher 2000;15:74-128. (Pubitemid 30176815)
204. Wilson HC, Lunn MPT, Schey S, et al. Successful treatment of IgM paraproteinaemic neuropathy with fludarabine. J Neurol Neurosurg Psychiatry 1999;66:575-580.
205. Wilson JR, Conwit RA, Eidelman BH, et al. Sensorimotor neuropathy resembling CIDP in patients receiving FK506. Muscle Nerve 1994;17:528-532.
206. Wolberg AS, Kon RH, Monroe DM, et al. Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations. Am J Hematol 2000;65:30-34.
207. Woodruff RK, Grigg AP, Firkin FC, et al. Fatal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients. Lancet 1986;ii:217-218.
208. Yu ZY, Lennon VA. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 1999;340:227-228. (Pubitemid 29063222)
209. Zettl UK, Gold R, Toyka KV, et al. Intravenous glucocorticosteroid treatment augments apoptosis of inflammatory T-cells in experimental autoimmune neuritis (EAN) of the Lewis rat. J Neuropathol Exp Neurol 1995;54:540-547.
210. Zhang G, Lopez PH, Li CY, et al. Anti-ganglioside antibody-mediated neuronal cytotoxicity and its protection by intravenous immunoglobulin: implications for immune neuropathies. Brain 2004;127:1085-1100.
211. Zonana-Nacach A, Barr SG, Magder LS, et al. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 2000;43:1801-1808.